The "Prescription Drug Sales Representative Disclosure Act" introduces new regulations for pharmaceutical sales representatives to help manage rising prescription drug costs. It requires pharmaceutical manufacturers to provide the Department of Business Regulation with a comprehensive list of their sales representatives who market prescription drugs in the state. This list must be updated within 60 days of any changes and filed annually. The Department will make this information available to healthcare providers and the public to promote transparency and compliance with the new regulations.

Additionally, the bill mandates that sales representatives disclose any compensation or gifts exceeding specified monetary thresholds given to healthcare providers. An annual fee of $55 per sales representative is imposed on manufacturers, along with civil penalties of up to $10,000 for those who fail to comply with the reporting requirements. The act is set to take effect on January 1, 2026, and aims to enhance accountability within the pharmaceutical industry by ensuring that the activities of sales representatives are properly documented and regulated. The bill does not include any deletions from current law, focusing solely on the new obligations for manufacturers.